Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis
Damiano Rondelli(University of Illinois Chicago), Robert S. Hoffman(New York City Department of Health and Mental Hygiene), Luis Isola(Mount Sinai Medical Center), Meir Wetzler, Josef T. Prchal(Huntsman Cancer Institute), Vesna Najfeld, Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Erin P. Demakos(Tisch Hospital), Vikas Gupta(Indian Institute of Technology Kanpur), Marco Scarano(Mario Negri Sud Foundation), Tsiporah B. Shore(Cornell University), Leah Price(Cwm Taf University Health Board), Giovanni Barosi(Policlinico San Matteo Fondazione), Andrea Bacigalupo(Università Cattolica del Sacro Cuore), Lewis R. Silverman(Icahn School of Medicine at Mount Sinai), Judith D. Goldberg(New York University), Roberto Marchioli, Rebecca B. Klisovic(Goethe University Frankfurt)
Cited by 3
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k